<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03346889</url>
  </required_header>
  <id_info>
    <org_study_id>2017/765 C</org_study_id>
    <nct_id>NCT03346889</nct_id>
  </id_info>
  <brief_title>Vestibular Outcomes in Vestibular Schwannoma</brief_title>
  <acronym>VOVS</acronym>
  <official_title>Vertigo Symptoms, Balance and Vestibular Function in Patients With Vestibular Schwannoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies have shown that vertigo is the symptoms that mostly affect quality of life&#xD;
      in patients with vestibular schwannoma. There is still limited knowledge as to why some&#xD;
      patients with this disorder develop vertigo, while others with the same diagnosis do not. The&#xD;
      purpose of this study is to measure symptom-related quality of life and to relate this to&#xD;
      objective disease characteristics at baseline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a longitudinal observational study with data collected at baseline and after&#xD;
      treatment.&#xD;
&#xD;
      Variables collected at baseline include age, sex, tumor size, location, type (cystic/solid),&#xD;
      tumor side, symptom variables including Dizziness Handicap Inventory, Vertigo Symptom Scale&#xD;
      Short Form, Haukeland Dizziness Questionnaire, Visual analog scale, Hospital Anxiety and&#xD;
      Depression Scale, RAND-12, dynamic posturography, video-based head impulse test, bithermal&#xD;
      caloric tests, ocular and cervical vestibular evoked myogenic potentials.&#xD;
&#xD;
      Follow-up data after 1 year are the same patient-reported outcomes as at baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 23, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Dizziness Handicap Inventory (DHI)</measure>
    <time_frame>Baseline and 1-year follow-up</time_frame>
    <description>25-item symptom score 0 - 100 points on dizziness handicap severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vertigo Symptom Scale Short Form</measure>
    <time_frame>Baseline and 1-year follow-up</time_frame>
    <description>15-item symptom score 0 - 60 points on vertigo symptom quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haukeland Dizziness Questionnaire (HDQ-10)</measure>
    <time_frame>Baseline and 1-year follow-up</time_frame>
    <description>10-item symptom score 0 - 30 points on vertigo symptom severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vertigo Visual Analog Scale</measure>
    <time_frame>Baseline and 1-year follow-up</time_frame>
    <description>100 mm visual analog scale on vertigo symptom severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Baseline and 1-year follow-up</time_frame>
    <description>14-item anxiety and depression score 0 - 42 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAND-12</measure>
    <time_frame>Baseline and 1-year follow-up</time_frame>
    <description>12-item health-related quality of life score</description>
  </secondary_outcome>
  <enrollment type="Actual">155</enrollment>
  <condition>Vestibular Schwannoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients in Norway with newly diagnosed vestibular schwannoma (VS) are referred to&#xD;
        Haukeland University Hospital for evaluation. The size of the study population therefore&#xD;
        depends on the incidence of VS in Norway and the inclusion period. The incidence of VS in&#xD;
        Norway is approximately 150 per year in a population of 5.2 million.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients living i Norway referred to Haukeland University Hospital due to newly&#xD;
             diagnosed, untreated vestibular schwannoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to undergo test protocol due to physical or language barriers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederik K Goplen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <state>Hordaland</state>
        <zip>5009</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vestibular evoked myogenic potentials</keyword>
  <keyword>head impulse testing</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurilemmoma</mesh_term>
    <mesh_term>Neuroma, Acoustic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

